AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Daré Bioscience has received a $3.6 million payment from the Gates Foundation under a grant agreement. The funding will support the development of a non-hormonal intravaginal contraceptive suitable for women in low- and middle-income countries. This is the next tranche of a $10.7 million grant, reflecting the company's progress on development milestones. Daré is focused on improving women's health through innovative products and solutions.
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet